Qameleon therapeutics announces orphan drug designation for Qamelostat (suberoylanilide hydroxamic acid)in late stage melanoma


Published on Friday, 10/28/2016


Qameleon therapeutics has obtained orphan drug designation by the FDA for vorinostat in late stage melanoma. Qameleon plans to further develop vorinostat in BRAF mutant, BRAF inhibitor resistant melanoma together with the Netherlands Cancer Institute in Amsterdam. First patients have been enrolled in a phase I trial.